Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

141. Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all‐comer population of patients with heart failure: a retrospective analysis Full Text available with Trip Pro

Therapeutic implications of a combined diagnostic workup including endomyocardial biopsy in an all‐comer population of patients with heart failure: a retrospective analysis Aetiology of heart failure (HF) often remains obscure. We therefore evaluated the usefulness of a combined diagnostic approach including cardiac magnetic resonance imaging (CMRI) and endomyocardial biopsy (EMB) to assess the cause of unexplained cardiomyopathy underlying HF.We retrospectively investigated 100 consecutive (...) patients (36% women, mean age 53.6 ± 18.8 years) presenting with unexplained cardiomyopathy (HF with reduced ejection fraction or left ventricular hypertrophy; excluding ischaemic and valvular heart disease; left ventricular ejection fraction 31.6 ± 13.9%, Left ventricular end-diastolic pressure 18.2 ± 9.3 mmHg, heart rate 89 ± 26.6 b.p.m.; mean ± SEM) at the University Medical Center Mainz. We performed electrocardiography, echocardiography, CMRI, and cardiac catheterization with EMB analysed

2018 ESC heart failure

142. Ivabradine (Lancora) - chronic heart failure

Ivabradine (Lancora) - chronic heart failure Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2018 Health Canada - Drug and Health Product Register

143. Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure

”. The application was transferred to IQWiG on 27 November 2015. According to the applicant, the method applied – hereinafter referred to as “PA pressure monitoring” – aims to detect early haemodynamic changes in the pulmonary circulation of heart failure patients to help optimize drug treatment and avoid symptoms, cardiac decompensation and hospitalization. Results from a randomized controlled trial (RCT) were available for the method “measurement and monitoring of pulmonary artery pressure via an implanted (...) Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure 1 Translation of the executive summary of the assessment of potential Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz (Version 1.0; Status: 8 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

144. Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure ? Addendum to Commission E15-04

Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure ? Addendum to Commission E15-04 1 Translation of the executive summary of the addendum Messung und Monitoring des pulmonalarteriellen Druckes mittels implantiertem Sensor zur Therapieoptimierung bei Herzinsuffizienz – Addendum zum Auftrag E15-04 (Version 1.0; Status: 20 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers (...) . However, solely the German original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. E16-02 Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure – Addendum to Commission E15-04 1 Executive summary of Addendum E16-02 Version 1.0 PA pressure monitoring in heart failure 20 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

145. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality Full Text available with Trip Pro

NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality The concept of natriuretic peptide guidance has been extensively studied in patients with chronic heart failure (HF), with only limited success. The effect of NT-proBNP (N-terminal probrain natriuretic peptide)-guided therapy in patients (...) versus conventional patients, P=0.39). Guided therapy also did not significantly improve any of the secondary end points.The PRIMA II trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?) demonstrates that the guidance of HF therapy to reach an NT-proBNP reduction of >30% after clinical stabilization did not improve 6-month outcomes.URL: http://www.trialregister.nl. Unique identifier: NTR3279.© 2017 American Heart

2018 EvidenceUpdates

146. Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education Full Text available with Trip Pro

Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education Heart failure education programs are not standardized. The best form of education is unclear. We evaluated whether addition of a novel tablet application to nurse practitioner (NP) education was superior to NP education alone in reducing 30-day readmission after heart failure hospitalization.From February 2015-March 2016, patients admitted to a quaternary academic center (...) with primary diagnosis of heart failure were randomized to 1) treatment - NP education plus tablet application (interactive conditional logic program that flags patient questions to medical staff), or 2) control - NP education. The primary outcome was reduction in 30-day readmission rate. Secondary outcomes included satisfaction and education assessed via survey.Randomization included 60 patients to treatment and 66 to control. A total of 13 patients withdrew prior to intervention (treatment n = 4, control

2018 EvidenceUpdates

147. Palliative care in the outpatient setting for patients with heart failure or advanced lung disease

Palliative care in the outpatient setting for patients with heart failure or advanced lung disease Palliative care in the outpatient setting for patients with heart failure or advanced lung disease Palliative care in the outpatient setting for patients with heart failure or advanced lung disease Lavenberg JG, Umscheid, CA Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Lavenberg JG, Umscheid, CA. Palliative care in the outpatient setting for patients with heart failure or advanced lung disease. Philadelphia: Center for Evidence-based Practice (CEP). 2018 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Heart Failure; Humans; Lung Diseases; Outpatients; Palliative Care; Quality of Life Language Published English Country of organisation United States English summary An English language summary is available. Address

2018 Health Technology Assessment (HTA) Database.

148. Failure of Invasive Airway Placement on the First Attempt Is Associated With Progression to Cardiac Arrest in Pediatric Acute Respiratory Compromise

Failure of Invasive Airway Placement on the First Attempt Is Associated With Progression to Cardiac Arrest in Pediatric Acute Respiratory Compromise PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2018 PedsCCM Evidence-Based Journal Club

149. Mitral valve interventions in heart failure Full Text available with Trip Pro

. Percutaneous edge-to-edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics. Further new transcatheter strategies addressing MR are evolving. The Carillion, Cardioband, and Mitralign devices were designed to reduce the annulus dilatation, which is a frequent and important determinant of secondary MR. Several transcatheter mitral valve replacement systems (Tendyne, CardiAQ (...) Mitral valve interventions in heart failure Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi-parametric approach. Severe secondary MR occurs in up to one-fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years

2018 ESC heart failure

150. Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference? Full Text available with Trip Pro

Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference? The early identification of patients with acute heart failure (AHF) is challenging as many other diseases lead to a clinical presentation with dyspnea.The aim of the study was to evaluate the impact of natriuretic peptides at common HF study cut-offs on the diagnosis of patients with dyspnea at admission.For this post hoc analysis, we analysed n = 726 European Union (EU (...) ) patients from the prospective BACH (Biomarkers in Acute Heart Failure) study. Cut-offs were 350 ng/L (BNP), 300 pmol/L [pro-atrial natriuretic peptide (proANP)], and 1800 ng/L (NT-proBNP). These cut-offs had equivalent 90 days' mortality in the EU cohort of BACH. We analysed the effect of selection using these cut-offs on the prevalence of the gold standard diagnoses made in the BACH study and the respective mortality. The prevalence of AHF is increased from 47.5 to 75.6% (NT-proBNP criteria) up

2018 ESC heart failure

151. ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end‐stage heart failure patients Full Text available with Trip Pro

ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end‐stage heart failure patients Ischaemic cardiomyopathy (ICM) leads to impaired contraction and ventricular dysfunction, causing high rates of morbidity and mortality. Epigenomics allows the identification of epigenetic signatures in human diseases. We analyse the differential epigenetic patterns of the ASB gene family in ICM patients and relate these alterations (...) to their haemodynamic and functional status.Epigenomic analysis was carried out using 16 left ventricular (LV) tissue samples, eight from ICM patients undergoing heart transplantation and eight from control (CNT) subjects without cardiac disease. We increased the sample size up to 13 ICM and 10 CNT for RNA sequencing and to 14 ICM for pyrosequencing analyses. We found a hypermethylated profile (cg11189868) in the ASB1 gene that showed a differential methylation of 0.26Δβ (P = 0.016). This result was validated

2018 ESC heart failure

152. Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy Full Text available with Trip Pro

Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a primary autosomal-dominant disorder of the myocardium with variable expressivity and penetrance. Occasionally, homozygous sarcomere genetic variants emerge while genotyping HCM patients. In these cases, a more severe HCM phenotype is generally seen. Here, we report a case of HCM that was diagnosed clinically at 39 years (...) of age. Initial symptoms were shortness of breath during exertion. Successively, he developed a wide array of severe clinical manifestations, which progressed to an ominous end-stage heart failure that resulted in heart transplantation. Genotype analysis revealed a missense MYBPC3 variant NM_000256.3:c.2618C>A,p.(Pro873His) that presented in the homozygous form. Conflicting interpretations of pathogenicity have been reported for the Pro873His MYBPC3 variant described here. Our patient, presenting

2018 ESC heart failure

153. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) Full Text available with Trip Pro

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups.The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142

2018 EvidenceUpdates

154. A Multivariable Prediction Model for Mortality in Individuals Admitted for Heart Failure (Abstract)

A Multivariable Prediction Model for Mortality in Individuals Admitted for Heart Failure To derive and validate a 30-day mortality clinical prediction rule for heart failure based on admission data and prior healthcare usage. A secondary objective was to determine the discriminatory function for mortality at 1 and 2 years.Observational cohort.Veterans Affairs inpatient medical centers (n=124).The derivation (2010-12; n=36,021) and validation (2013-15; n=30,364) cohorts included randomly

2018 EvidenceUpdates

155. Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes Full Text available with Trip Pro

Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes Cross correlation analysis (CCA) using tissue Doppler imaging has been shown to be associated with outcome after cardiac resynchronization therapy (CRT) in patients with heart failure (HF) with wide QRS. However, its significance in patients with narrow QRS treated with CRT is unknown.The aim of the current study was to investigate the association of mechanical activation delay by CCA with study outcome (...) -On group showed a significant increase in unfavorable events (hazard ratio: 3.73; 95% confidence interval: 1.15 to 12.14; p = 0.03).In the EchoCRT population, absence of delayed mechanical activation by CCA was significantly associated with poor outcomes, possibly due to the onset of new delayed mechanical activation with CRT pacing. (Echocardiography Guided Cardiac Resynchronization Therapy [EchoCRT] Trial; NCT00683696).Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier

2018 EvidenceUpdates

156. Prevalence, clinical correlates, and outcomes of anaemia in multi‐ethnic Asian patients with heart failure with reduced ejection fraction Full Text available with Trip Pro

studied 3886 Asian patients (60 ± 13 years, 21% women) with HF (ejection fraction ≤40%) from 11 regions in the Asian Sudden Cardiac Death in Heart Failure study. Anaemia was defined as haemoglobin <13 g/dL (men) and <12 g/dL (women). Ethnic groups included Chinese (33.0%), Indian (26.2%), Malay (15.1%), Japanese/Korean (20.2%), and others (5.6%). Overall, anaemia was present in 41%, with a wide range across ethnicities (33-54%). Indian ethnicity, older age, diabetes, and chronic kidney disease were (...) Prevalence, clinical correlates, and outcomes of anaemia in multi‐ethnic Asian patients with heart failure with reduced ejection fraction Recent international heart failure (HF) guidelines recognize anaemia as an important comorbidity contributing to poor outcomes in HF, based on data mainly from Western populations. We sought to determine the prevalence, clinical correlates, and prognostic impact of anaemia in patients with HF with reduced ejection fraction across Asia.We prospectively

2018 ESC heart failure

157. Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice Full Text available with Trip Pro

Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice Chemotherapy-induced cardiotoxicity resulting in heart failure (HF) is one of the most dreaded complications of cancer therapy that can significantly impact morbidity and mortality. With a high prevalence of cardiovascular disease in cancer patients, the risk of developing HF is significantly increased. A new discipline of Onco (...) -Cardiology has evolved to address the cardiovascular needs of patients with cancer, however, there is limited evidence-based data to guide clinical decision-making in the management of the cardiovascular complications of cancer therapy. The department of cardiology at MD Anderson Cancer Center initiated the MD Anderson Practice (MAP) project and developed algorithms to guide the management of the cardiovascular complications of cancer therapy. For chemotherapy-induced HF, we initiated the Heart Success

2018 Frontiers in cardiovascular medicine

158. Diuretic dosing in heart failure: more data are needed Full Text available with Trip Pro

Diuretic dosing in heart failure: more data are needed 29575802 2018 11 14 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Diuretic dosing in heart failure: more data are needed. 649-650 10.1002/ehf2.12229 De Vecchis Renato R Cardiology Unit, Presidio Sanitario Intermedio "Elena d'Aosta", via Cagnazzi 29, c.a.p, 80137, Napoli, Italy. Rigopoulos Angelos A Department of Internal Medicine III, Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle (...) England ESC Heart Fail 101669191 2055-5822 0 Diuretics 7LXU5N7ZO5 Furosemide IM ESC Heart Fail. 2018 Feb;5(1):87-94 28967699 Diuretics Furosemide Heart Failure Humans 2017 08 10 2017 09 25 2018 3 27 6 0 2018 11 15 6 0 2018 3 26 6 0 ppublish 29575802 10.1002/ehf2.12229 PMC6073013 ESC Heart Fail. 2018 Feb;5(1):87-94 28967699 Clin Drug Investig. 2017 Apr;37(4):327-342 27766511 ESC Heart Fail. 2018 Mar 25;:null 29575802 Am J Med. 2016 Dec;129(12):1299-1306 27542612 J Card Fail. 2010 Dec;16(12):922-30

2018 ESC heart failure

159. The impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure Full Text available with Trip Pro

The impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure This study aimed to evaluate the impact of aerobic exercise training with vascular occlusion in patients with chronic heart failure.Thirty patients with post-infarction heart failure were randomized to an interventional exercise group (IG; n = 15) or a control exercise group (CG; n = 15). Exercise was performed at an intensity of 40-70% of the peak VO2 /W for 6 months. Patients in the IG (...) characteristics at study entry. Peak VO2 /W in the IG significantly increased compared with that in the CG; the change in the serum BNP levels was significantly larger in the IG than in the CG.These results suggest that aerobic exercise training with vascular occlusion can improve exercise capacity and serum BNP levels in patients with chronic heart failure.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure Controlled trial quality: uncertain

160. Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction Full Text available with Trip Pro

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction The mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF) are not yet elucidated. Chronotropic incompetence has emerged as a potential mechanism. We aimed to evaluate whether heart rate (HR) response to exercise is associated to functional capacity in patients with symptomatic HFpEF.We prospectively studied 74 HFpEF patients [35.1% New York (...) positively associated with peak VO2 . We found a linear relationship between Delta-HR and peak VO2 (β coefficient of 0.03; 95% confidence interval: 0.004-0.05; P = 0.030); conversely, the association among CIs and peak VO2 was exponentially shaped.In patients with chronic HFpEF, the HR response to exercise was positively associated to patient's functional capacity.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure